Silverback Logo

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC™ technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
© Copyright 2021 - Silverback Therapeutics®